Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients

Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients

BackgroundImatinib is the most widely used tyrosine kinase inhibitor (TKI) in patients with newly diagnosed chronic-phase chronic myeloid leukemia(CML-CP). However, failure to achieve optimal response after imatinib administration, and subsequent switch to second-generation TKI therapy results in po...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Yuxin Li, Yilin Zhang, Jin Wang, Aili He, Wanggang Zhang, Xingmei Cao, Yinxia Chen, Jie Liu, Pengyu Zhang, Jianli Wang, Wanhong Zhao, Yun Yang, Xin Meng, Sheping Chen, Longjin Zhang, Ting Wang, Xugeng Wang, Xiaorong Ma
Formaat: Artikel
Taal:English
Gepubliceerd in: Frontiers Media S.A. 2024-06-01
Reeks:Frontiers in Oncology
Onderwerpen:
chronic phase chronic myeloid leukemia
imatinib
prognostic model
nomogram
Sokal score
Euro score
Online toegang:https://www.frontiersin.org/articles/10.3389/fonc.2024.1418417/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1418417/full

Gelijkaardige items